Omega Therapeutics

54 articles about Omega Therapeutics

• Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

  5/4/2023

  Omega Therapeutics today announced financial results for the first quarter ended March 31, 2023, and highlighted recent Company progress.

• Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

  4/27/2023

  Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced that it will present new preclinical data related to its MYC-HCC and MYC-NSCLC programs at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois, June 2 – 6, 2023.

• Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

  3/30/2023

  Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial.

• Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

  3/1/2023

  Omega Therapeutics, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

• Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

  2/23/2023

  Omega Therapeutics, Inc. today announced that it has entered into a securities purchase agreement with investors in a registered direct offering of 6,920,415 shares of common stock (the “Shares”) at a purchase price of $5.78 per share, resulting in gross proceeds of approximately $40 million.

• Omega Therapeutics to Participate in the Piper Sandler 34th Annual Healthcare Conference

  11/17/2022

  Omega Therapeutics, Inc. today announced that management will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Thursday, December 1, 2022, at 8:00 a.m. ET. 

• Omega Therapeutics Named One of BioSpace's 2023 Best Places to Work

  11/15/2022

  Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as a new class of programmable epigenetic medicines, today announced that it has been named among BioSpace's Best Places to Work.

• Omega Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

  11/8/2022

  Omega Therapeutics, Inc. today announced financial results for the third quarter ended September 30, 2022 and highlighted recent Company progress.

• Omega Therapeutics to Participate in the Jefferies 2022 London Healthcare Conference

  11/3/2022

  Omega Therapeutics, Inc. announced that management will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 15, 2022, at 11:30 a.m. GMT.

• Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma

  11/2/2022

  Omega Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for OTX-2002, the company's first-in-class epigenomic controller engineered to downregulate c-Myc (MYC), for the treatment of hepatocellular carcinoma (HCC).

• Omega Therapeutics Announces First Patient Dosed in Landmark MYCHELANGELO™ I Trial of OTX-2002 in Hepatocellular Carcinoma and Other Solid Tumor Types Associated with the MYC Oncogene

  10/27/2022

  Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega") today announced dosing of the first patient in its Phase 1/2 MYCHELANGELO™ I trial evaluating OTX-2002 for the treatment of relapsed or refractory hepatocellular carcinoma (HCC) and other solid tumor types associated with c-Myc (MYC) oncogene overexpression. OTX-2002.

• Omega Therapeutics to Participate in Two Upcoming Investor Conferences

  9/26/2022

  Omega Therapeutics, Inc. today announced that members of management will participate in two upcoming investor conferences.

• 

  Small and Medium Biotech Companies Still Growing in Uncertain Times

  9/6/2022

  BioSpace spoke with three CEOs: Alto Neuroscience’s Dr. Amit Etkin, Omega Therapeutics’ Mahesh Karande and Rain Therapeutics’ Avanish Vellanki about their companies' employment growth.

• Omega Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

  9/6/2022

  Omega Therapeutics, Inc. (NASDAQ: OMGA) ("Omega"), today announced that management will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference.

• Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

  9/1/2022

  Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), today announced the appointment of Rainer Boehm as an independent director to its Board of Directors.

• Omega Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

  8/4/2022

  Omega Therapeutics, Inc. announced financial results for the second quarter ended June 30, 2022, and highlighted recent Company progress.

• Omega Therapeutics to Participate in the 2022 Wedbush PacGrow Healthcare Conference

  8/3/2022

  Omega Therapeutics, Inc., a clinical-stage biotechnology company pioneering the first systematic approach to use mRNA therapeutics as programmable epigenetic medicines by leveraging its OMEGA Epigenomic Programing™ platform, announced that Thomas McCauley, Chief Scientific Officer, will participate in a fireside chat at the 2022 Wedbush PacGrow Healthcare Conference on August 10, 2022, at 8 a.m. ET.

• 

  Omega Gets FDA Nod to Start First-Ever Epigenomic Controller Trial

  7/15/2022

  Omega Therapeutics announced Thursday that the Investigational New Drug (IND) application for its hepatocellular carcinoma (HCC) candidate OTX-2002 has been granted by the FDA.

• Omega Therapeutics Announces FDA Clearance of IND Application for OTX-2002, First Omega Epigenomic Controller, for MYC Driven Hepatocellular Carcinoma

  7/14/2022

  Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), today announced that it has received clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) to initiate a Phase 1/2, first-in-human, clinical study of OTX-2002 for the treatment of hepatocellular carcinoma (HCC).

• Omega Therapeutics Presents New Preclinical Data Supporting the First Epigenomic Controller, OTX-2002, as a Potential Therapeutic Approach in Hepatocellular Carcinoma at the ESMO 2022 World Congress on Gastrointestinal Cancer

  6/30/2022

  Omega Therapeutics, Inc. announces the presentation of new preclinical data on its lead product candidate, OTX-2002, to regulate expression of the c-Myc (MYC) oncogene through epigenetic modulation in multiple models of hepatocellular carcinoma (HCC) in a poster presentation at the European Society of Medical Oncology (ESMO) 2022 World Congress on Gastrointestinal (GI) Cancer, taking place in Barcelona, Spain, June 29 – July 2, 2022.